“Shift Toward Targeted Therapies and Precision Diagnostics”
- A major and evolving trend in the Europe HDV infection market is the transition from conventional interferon-based treatments to targeted antiviral therapies and precision diagnostic approaches, aiming for better disease management and improved patient outcomes
- For instance, the European Medicines Agency (EMA) granted conditional approval for Hepcludex (bulevirtide), the first-in-class entry inhibitor for HDV, marking a significant breakthrough in treatment for chronic HDV patients. Its growing clinical acceptance is reshaping treatment protocols across Europe
- In addition, the adoption of advanced molecular diagnostic tools, including HDV RNA quantification assays and genotyping, is enabling earlier and more accurate diagnosis, essential for initiating timely intervention and improving prognosis
- National health systems in countries such as Germany, Italy, and France are increasingly integrating HDV screening into broader hepatitis B programs, particularly among high-risk populations such as migrants, intravenous drug users, and individuals co-infected with HIV
- This trend toward personalized medicine is being supported by rising research funding, real-world evidence collection, and strategic partnerships between academic institutions and pharmaceutical companies
- As healthcare systems prioritize elimination goals for viral hepatitis, the demand for novel treatment options and sensitive diagnostics is expected to surge, setting the stage for continued innovation and market expansion
